Annual SG&A
$47.58 M
-$42.60 M-47.24%
31 December 2023
Summary:
Inovio Pharmaceuticals annual selling, general & administrative expenses is currently $47.58 million, with the most recent change of -$42.60 million (-47.24%) on 31 December 2023. During the last 3 years, it has risen by +$10.33 million (+27.74%). INO annual SG&A is now -47.24% below its all-time high of $90.19 million, reached on 31 December 2022.INO Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$8.61 M
-$1.59 M-15.61%
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly selling, general & administrative expenses is currently $8.61 million, with the most recent change of -$1.59 million (-15.61%) on 30 September 2024. Over the past year, it has dropped by -$1.31 million (-13.21%). INO quarterly SG&A is now -82.22% below its all-time high of $48.46 million, reached on 30 June 2022.INO Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$6.67 B
-$112.88 M-1.72%
30 September 2024
Summary:
Inovio Pharmaceuticals TTM selling, general & administrative expenses is currently -$6.67 billion, with the most recent change of -$112.88 million (-1.72%) on 30 September 2024. Over the past year, it has dropped by -$6.72 billion (-13110.23%). INO TTM SG&A is now -38250.06% below its all-time high of $91.62 million, reached on 30 June 2022.INO TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -47.2% | -13.2% | -10000.0% |
| 3 y3 years | +27.7% | -34.5% | -10000.0% |
| 5 y5 years | +62.3% | +51.6% | -10000.0% |
INO Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -47.2% | +27.7% | -82.2% | at low | -66.3% | at low |
| 5 y | 5 years | -47.2% | +74.9% | -82.2% | +51.6% | -151.7% | at low |
| alltime | all time | -47.2% | +1200.7% | -82.2% | +1956.8% | <-9999.0% | at low |
Inovio Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.61 M(-15.6%) | $39.64 M(-3.2%) |
| June 2024 | - | $10.21 M(-3.4%) | $40.95 M(-7.5%) |
| Mar 2024 | - | $10.57 M(+3.2%) | $44.26 M(-7.0%) |
| Dec 2023 | $47.58 M(-47.2%) | $10.24 M(+3.2%) | $47.58 M(-7.2%) |
| Sept 2023 | - | $9.93 M(-26.6%) | $51.29 M(-3.6%) |
| June 2023 | - | $13.52 M(-2.6%) | $53.19 M(-39.6%) |
| Mar 2023 | - | $13.89 M(-0.4%) | $88.12 M(-2.3%) |
| Dec 2022 | $90.19 M(+67.8%) | $13.95 M(+18.0%) | $90.19 M(-0.1%) |
| Sept 2022 | - | $11.82 M(-75.6%) | $90.28 M(-1.5%) |
| June 2022 | - | $48.46 M(+203.7%) | $91.62 M(+64.1%) |
| Mar 2022 | - | $15.95 M(+13.6%) | $55.82 M(+3.9%) |
| Dec 2021 | $53.75 M(+44.3%) | $14.05 M(+6.8%) | $53.75 M(+11.2%) |
| Sept 2021 | - | $13.16 M(+3.9%) | $48.32 M(+6.7%) |
| June 2021 | - | $12.67 M(-8.8%) | $45.28 M(+3.7%) |
| Mar 2021 | - | $13.88 M(+61.1%) | $43.68 M(+17.3%) |
| Dec 2020 | $37.25 M(+36.9%) | $8.62 M(-14.8%) | $37.25 M(-0.2%) |
| Sept 2020 | - | $10.11 M(-8.7%) | $37.33 M(+13.5%) |
| June 2020 | - | $11.07 M(+48.6%) | $32.90 M(+18.9%) |
| Mar 2020 | - | $7.45 M(-14.4%) | $27.68 M(+1.7%) |
| Dec 2019 | $27.20 M(-7.2%) | $8.70 M(+53.1%) | $27.20 M(+12.7%) |
| Sept 2019 | - | $5.68 M(-2.9%) | $24.14 M(-4.4%) |
| June 2019 | - | $5.85 M(-16.1%) | $25.25 M(-5.0%) |
| Mar 2019 | - | $6.97 M(+23.8%) | $26.59 M(-9.3%) |
| Dec 2018 | $29.32 M(+3.6%) | $5.64 M(-17.0%) | $29.32 M(-7.6%) |
| Sept 2018 | - | $6.79 M(-5.5%) | $31.71 M(+1.5%) |
| June 2018 | - | $7.19 M(-25.9%) | $31.24 M(+3.4%) |
| Mar 2018 | - | $9.70 M(+20.7%) | $30.22 M(+6.8%) |
| Dec 2017 | $28.29 M(+18.4%) | $8.03 M(+27.1%) | $28.29 M(+3.9%) |
| Sept 2017 | - | $6.32 M(+2.4%) | $27.22 M(+2.1%) |
| June 2017 | - | $6.17 M(-20.6%) | $26.66 M(+1.4%) |
| Mar 2017 | - | $7.77 M(+11.5%) | $26.29 M(+10.0%) |
| Dec 2016 | $23.89 M(+32.3%) | $6.97 M(+21.0%) | $23.89 M(+9.7%) |
| Sept 2016 | - | $5.76 M(-0.8%) | $21.79 M(+6.8%) |
| June 2016 | - | $5.80 M(+8.0%) | $20.41 M(+5.6%) |
| Mar 2016 | - | $5.37 M(+10.5%) | $19.33 M(+7.0%) |
| Dec 2015 | $18.06 M(+13.9%) | $4.86 M(+11.0%) | $18.06 M(+3.6%) |
| Sept 2015 | - | $4.38 M(-7.2%) | $17.43 M(+7.6%) |
| June 2015 | - | $4.72 M(+14.9%) | $16.20 M(+2.3%) |
| Mar 2015 | - | $4.11 M(-2.8%) | $15.83 M(-0.2%) |
| Dec 2014 | $15.86 M(+16.2%) | $4.22 M(+34.0%) | $15.86 M(-0.7%) |
| Sept 2014 | - | $3.15 M(-27.5%) | $15.97 M(-0.8%) |
| June 2014 | - | $4.35 M(+5.2%) | $16.10 M(+8.8%) |
| Mar 2014 | - | $4.13 M(-4.8%) | $14.80 M(+8.5%) |
| Dec 2013 | $13.64 M(+26.6%) | $4.34 M(+32.2%) | $13.64 M(+11.6%) |
| Sept 2013 | - | $3.28 M(+7.8%) | $12.22 M(+5.2%) |
| June 2013 | - | $3.05 M(+2.4%) | $11.61 M(+3.1%) |
| Mar 2013 | - | $2.97 M(+1.9%) | $11.26 M(+4.5%) |
| Dec 2012 | $10.78 M(-10.1%) | $2.92 M(+9.1%) | $10.78 M(-3.0%) |
| Sept 2012 | - | $2.67 M(-0.8%) | $11.11 M(+3.3%) |
| June 2012 | - | $2.70 M(+8.4%) | $10.76 M(-3.5%) |
| Mar 2012 | - | $2.49 M(-23.5%) | $11.16 M(-6.9%) |
| Dec 2011 | $11.99 M | $3.25 M(+40.1%) | $11.99 M(+0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $2.32 M(-24.9%) | $11.88 M(-4.5%) |
| June 2011 | - | $3.09 M(-6.8%) | $12.44 M(+0.5%) |
| Mar 2011 | - | $3.32 M(+5.4%) | $12.38 M(+2.2%) |
| Dec 2010 | $12.11 M(-11.4%) | $3.15 M(+9.2%) | $12.11 M(+5.0%) |
| Sept 2010 | - | $2.88 M(-4.8%) | $11.53 M(-7.6%) |
| June 2010 | - | $3.03 M(-0.7%) | $12.48 M(-9.3%) |
| Mar 2010 | - | $3.05 M(+18.6%) | $13.75 M(+0.6%) |
| Dec 2009 | $13.67 M(+36.6%) | $2.57 M(-32.9%) | $13.67 M(-0.1%) |
| Sept 2009 | - | $3.83 M(-10.9%) | $13.69 M(+16.1%) |
| June 2009 | - | $4.30 M(+45.0%) | $11.78 M(+11.5%) |
| Mar 2009 | - | $2.97 M(+14.6%) | $10.57 M(+5.6%) |
| Dec 2008 | $10.01 M(-9.7%) | $2.59 M(+34.2%) | $10.01 M(-6.3%) |
| Sept 2008 | - | $1.93 M(-37.5%) | $10.68 M(-10.5%) |
| June 2008 | - | $3.09 M(+28.5%) | $11.93 M(+6.6%) |
| Mar 2008 | - | $2.40 M(-26.5%) | $11.19 M(+1.5%) |
| Dec 2007 | $11.08 M(+33.4%) | $3.27 M(+2.8%) | $11.02 M(+4.5%) |
| Sept 2007 | - | $3.18 M(+35.5%) | $10.55 M(+14.1%) |
| June 2007 | - | $2.34 M(+4.9%) | $9.24 M(+5.9%) |
| Mar 2007 | - | $2.23 M(-20.0%) | $8.73 M(+5.1%) |
| Dec 2006 | $8.30 M(+34.2%) | $2.79 M(+49.3%) | $8.30 M(+12.6%) |
| Sept 2006 | - | $1.87 M(+2.4%) | $7.38 M(+8.6%) |
| June 2006 | - | $1.83 M(+0.7%) | $6.80 M(+4.1%) |
| Mar 2006 | - | $1.81 M(-2.7%) | $6.53 M(+5.5%) |
| Dec 2005 | $6.19 M(+1.0%) | $1.87 M(+44.8%) | $6.19 M(+0.4%) |
| Sept 2005 | - | $1.29 M(-17.5%) | $6.17 M(-5.0%) |
| June 2005 | - | $1.56 M(+6.0%) | $6.49 M(-0.3%) |
| Mar 2005 | - | $1.47 M(-20.1%) | $6.50 M(+6.1%) |
| Dec 2004 | $6.13 M(+34.2%) | $1.84 M(+14.5%) | $6.13 M(+10.8%) |
| Sept 2004 | - | $1.61 M(+2.0%) | $5.53 M(+10.7%) |
| June 2004 | - | $1.58 M(+43.9%) | $5.00 M(+13.6%) |
| Mar 2004 | - | $1.10 M(-12.0%) | $4.40 M(-3.6%) |
| Dec 2003 | $4.57 M(+24.8%) | $1.25 M(+15.9%) | $4.57 M(+8.1%) |
| Sept 2003 | - | $1.08 M(+9.9%) | $4.22 M(+3.2%) |
| June 2003 | - | $979.60 K(-22.5%) | $4.09 M(+1.2%) |
| Mar 2003 | - | $1.26 M(+39.8%) | $4.04 M(+10.5%) |
| Dec 2002 | $3.66 M(-7.9%) | $903.60 K(-4.5%) | $3.66 M(+32.8%) |
| Sept 2002 | - | $946.40 K(+1.7%) | $2.75 M(-19.5%) |
| June 2002 | - | $930.40 K(+6.0%) | $3.42 M(-29.1%) |
| Mar 2002 | - | $877.90 K(-45.6%) | $4.83 M(-12.9%) |
| Dec 2001 | $3.97 M(-10.5%) | - | - |
| Sept 2001 | - | $1.61 M(-30.9%) | $5.54 M(-3.8%) |
| June 2001 | - | $2.34 M(+457.9%) | $5.76 M(+16.0%) |
| Mar 2001 | - | $418.80 K(-64.3%) | $4.97 M(-15.2%) |
| Mar 2001 | $4.44 M(-20.9%) | - | - |
| Dec 2000 | - | $1.17 M(-36.0%) | $5.86 M(-0.5%) |
| Sept 2000 | - | $1.83 M(+18.7%) | $5.89 M(+7.9%) |
| June 2000 | - | $1.54 M(+17.7%) | $5.45 M(-1.0%) |
| Mar 2000 | $5.61 M(+2.0%) | $1.31 M(+9.2%) | $5.51 M(-6.6%) |
| Dec 1999 | - | $1.20 M(-14.3%) | $5.90 M(-4.8%) |
| Sept 1999 | - | $1.40 M(-12.5%) | $6.20 M(+29.2%) |
| June 1999 | - | $1.60 M(-5.9%) | $4.80 M(+50.0%) |
| Mar 1999 | $5.50 M | $1.70 M(+13.3%) | $3.20 M(+113.3%) |
| Dec 1998 | - | $1.50 M | $1.50 M |
FAQ
- What is Inovio Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual SG&A year-on-year change?
- What is Inovio Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly SG&A year-on-year change?
- What is Inovio Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals TTM SG&A year-on-year change?
What is Inovio Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of INO is $47.58 M
What is the all time high annual SG&A for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual selling, general & administrative expenses is $90.19 M
What is Inovio Pharmaceuticals annual SG&A year-on-year change?
Over the past year, INO annual selling, general & administrative expenses has changed by -$42.60 M (-47.24%)
What is Inovio Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of INO is $8.61 M
What is the all time high quarterly SG&A for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $48.46 M
What is Inovio Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, INO quarterly selling, general & administrative expenses has changed by -$1.31 M (-13.21%)
What is Inovio Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of INO is -$6.67 B
What is the all time high TTM SG&A for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM selling, general & administrative expenses is $91.62 M
What is Inovio Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, INO TTM selling, general & administrative expenses has changed by -$6.72 B (-13110.23%)